 Jeffrey Kern
Concepts (290)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Neoplasms | 25 | 2024 | 2490 | 2.400 |
Why?
| | Receptor, ErbB-2 | 14 | 2019 | 342 | 2.400 |
Why?
| | Neuregulin-1 | 9 | 2019 | 46 | 2.370 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 17 | 2024 | 1079 | 1.700 |
Why?
| | Lung | 13 | 2019 | 4046 | 1.460 |
Why?
| | Signal Transduction | 10 | 2019 | 5077 | 1.100 |
Why?
| | Respiratory Mucosa | 4 | 2014 | 322 | 1.030 |
Why?
| | Antineoplastic Agents, Immunological | 3 | 2022 | 190 | 0.910 |
Why?
| | Acute Lung Injury | 3 | 2012 | 284 | 0.900 |
Why?
| | Radiosurgery | 2 | 2024 | 346 | 0.840 |
Why?
| | Pneumonectomy | 1 | 2024 | 154 | 0.780 |
Why?
| | ErbB Receptors | 7 | 2014 | 616 | 0.770 |
Why?
| | Receptor, ErbB-3 | 6 | 2007 | 44 | 0.680 |
Why?
| | Epithelium | 2 | 2019 | 315 | 0.660 |
Why?
| | Protein-Tyrosine Kinases | 2 | 2019 | 434 | 0.660 |
Why?
| | Adult Stem Cells | 1 | 2019 | 41 | 0.630 |
Why?
| | Small Cell Lung Carcinoma | 1 | 2020 | 94 | 0.620 |
Why?
| | Alveolar Epithelial Cells | 1 | 2019 | 114 | 0.600 |
Why?
| | Neuroendocrine Cells | 2 | 2016 | 32 | 0.590 |
Why?
| | Adenocarcinoma | 5 | 2019 | 934 | 0.580 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2019 | 328 | 0.540 |
Why?
| | Immunotherapy | 2 | 2022 | 645 | 0.540 |
Why?
| | Neoplasm Staging | 8 | 2024 | 1376 | 0.510 |
Why?
| | Neoplasm Proteins | 1 | 2019 | 432 | 0.510 |
Why?
| | Tomography, X-Ray Computed | 7 | 2015 | 2670 | 0.510 |
Why?
| | STAT3 Transcription Factor | 5 | 2009 | 202 | 0.470 |
Why?
| | Adherens Junctions | 1 | 2014 | 25 | 0.460 |
Why?
| | Interleukin-6 | 1 | 2019 | 771 | 0.460 |
Why?
| | B-Lymphocyte Subsets | 1 | 2014 | 75 | 0.420 |
Why?
| | Immunity, Humoral | 1 | 2014 | 118 | 0.410 |
Why?
| | Cell Adhesion | 1 | 2014 | 466 | 0.410 |
Why?
| | Pulmonary Fibrosis | 2 | 2007 | 397 | 0.390 |
Why?
| | beta Catenin | 1 | 2014 | 251 | 0.390 |
Why?
| | Epithelial Cells | 3 | 2011 | 1097 | 0.390 |
Why?
| | Blood Coagulation Factors | 1 | 2012 | 54 | 0.380 |
Why?
| | Carcinoma, Squamous Cell | 4 | 2019 | 683 | 0.380 |
Why?
| | Adenocarcinoma, Bronchiolo-Alveolar | 1 | 2012 | 19 | 0.380 |
Why?
| | Quality of Life | 1 | 2024 | 2847 | 0.380 |
Why?
| | Protein C | 1 | 2012 | 59 | 0.380 |
Why?
| | Smad3 Protein | 1 | 2011 | 43 | 0.360 |
Why?
| | Smad2 Protein | 1 | 2011 | 38 | 0.360 |
Why?
| | Trans-Activators | 2 | 2004 | 399 | 0.340 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2011 | 165 | 0.330 |
Why?
| | Receptors, Cell Surface | 1 | 2012 | 391 | 0.330 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2011 | 283 | 0.330 |
Why?
| | Neoplasms | 3 | 2024 | 2655 | 0.320 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 2012 | 654 | 0.310 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2011 | 212 | 0.310 |
Why?
| | Lung Diseases | 2 | 2016 | 768 | 0.310 |
Why?
| | Permeability | 4 | 2014 | 161 | 0.300 |
Why?
| | Quinazolines | 5 | 2014 | 249 | 0.300 |
Why?
| | Humans | 46 | 2024 | 136899 | 0.300 |
Why?
| | Early Detection of Cancer | 1 | 2013 | 419 | 0.300 |
Why?
| | Prenylation | 1 | 2008 | 3 | 0.290 |
Why?
| | Phosphorylation | 6 | 2019 | 1762 | 0.290 |
Why?
| | Antibodies, Monoclonal | 5 | 2007 | 1417 | 0.280 |
Why?
| | Piperidines | 1 | 2008 | 207 | 0.250 |
Why?
| | Protein Kinase Inhibitors | 4 | 2014 | 919 | 0.250 |
Why?
| | Tomography, Emission-Computed | 2 | 2003 | 71 | 0.250 |
Why?
| | DNA-Binding Proteins | 2 | 2004 | 1502 | 0.240 |
Why?
| | Epidermal Growth Factor | 3 | 2012 | 174 | 0.230 |
Why?
| | Drug Eruptions | 2 | 2024 | 28 | 0.220 |
Why?
| | Pyridines | 1 | 2008 | 504 | 0.220 |
Why?
| | Autocrine Communication | 1 | 2004 | 41 | 0.220 |
Why?
| | Thoracic Surgery, Video-Assisted | 1 | 2024 | 43 | 0.220 |
Why?
| | Morphogenesis | 1 | 2004 | 166 | 0.210 |
Why?
| | Mediastinal Neoplasms | 1 | 2003 | 45 | 0.210 |
Why?
| | Enzyme Inhibitors | 2 | 2004 | 845 | 0.210 |
Why?
| | Mass Screening | 1 | 2012 | 1262 | 0.210 |
Why?
| | Skin Diseases | 2 | 2024 | 149 | 0.200 |
Why?
| | Genetic Therapy | 1 | 2005 | 295 | 0.200 |
Why?
| | Cell Line, Tumor | 6 | 2019 | 3396 | 0.200 |
Why?
| | Milk Proteins | 1 | 2002 | 34 | 0.200 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2004 | 366 | 0.190 |
Why?
| | Cisplatin | 2 | 2020 | 316 | 0.190 |
Why?
| | ADAM17 Protein | 2 | 2012 | 35 | 0.190 |
Why?
| | Cell Line | 4 | 2014 | 2847 | 0.190 |
Why?
| | Aged, 80 and over | 8 | 2024 | 7552 | 0.180 |
Why?
| | Cell Proliferation | 4 | 2015 | 2471 | 0.180 |
Why?
| | Radiopharmaceuticals | 1 | 2002 | 178 | 0.180 |
Why?
| | ADAM Proteins | 2 | 2012 | 61 | 0.180 |
Why?
| | Fluorodeoxyglucose F18 | 1 | 2002 | 135 | 0.180 |
Why?
| | RNA Interference | 2 | 2014 | 463 | 0.180 |
Why?
| | Animals | 10 | 2021 | 36915 | 0.180 |
Why?
| | CTLA-4 Antigen | 1 | 2021 | 99 | 0.170 |
Why?
| | Recombinant Proteins | 3 | 2011 | 1357 | 0.170 |
Why?
| | Etoposide | 1 | 2020 | 152 | 0.160 |
Why?
| | Enzyme Induction | 1 | 2019 | 90 | 0.160 |
Why?
| | Female | 15 | 2024 | 72703 | 0.160 |
Why?
| | RNA, Neoplasm | 1 | 2019 | 82 | 0.160 |
Why?
| | Tight Junctions | 2 | 2014 | 77 | 0.160 |
Why?
| | Receptors, Interleukin-6 | 1 | 2019 | 43 | 0.150 |
Why?
| | Antigens | 1 | 2021 | 358 | 0.150 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2021 | 251 | 0.150 |
Why?
| | B7-H1 Antigen | 1 | 2021 | 218 | 0.150 |
Why?
| | Cells, Cultured | 3 | 2019 | 4204 | 0.150 |
Why?
| | Sirolimus | 1 | 2020 | 275 | 0.150 |
Why?
| | Enzyme Activation | 2 | 2014 | 816 | 0.150 |
Why?
| | Transfection | 3 | 2011 | 948 | 0.150 |
Why?
| | Hyperplasia | 2 | 2016 | 175 | 0.140 |
Why?
| | Cell Lineage | 1 | 2019 | 346 | 0.140 |
Why?
| | Male | 14 | 2024 | 67308 | 0.140 |
Why?
| | Mice | 6 | 2019 | 17775 | 0.140 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2020 | 857 | 0.140 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2020 | 410 | 0.140 |
Why?
| | Middle Aged | 9 | 2024 | 33118 | 0.130 |
Why?
| | RNA, Messenger | 3 | 2019 | 2837 | 0.130 |
Why?
| | Aged | 8 | 2024 | 23641 | 0.130 |
Why?
| | Longitudinal Studies | 1 | 2024 | 2844 | 0.130 |
Why?
| | Antigen Presentation | 1 | 2017 | 216 | 0.130 |
Why?
| | Immunosuppressive Agents | 1 | 2021 | 886 | 0.130 |
Why?
| | Lung Diseases, Obstructive | 1 | 2016 | 50 | 0.130 |
Why?
| | Cytokines | 1 | 2024 | 2078 | 0.130 |
Why?
| | Tumor Cells, Cultured | 4 | 2013 | 950 | 0.120 |
Why?
| | Treatment Outcome | 4 | 2024 | 10768 | 0.120 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 4 | 2013 | 974 | 0.120 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2017 | 209 | 0.120 |
Why?
| | Neoplastic Stem Cells | 1 | 2019 | 398 | 0.120 |
Why?
| | Research Report | 1 | 2016 | 83 | 0.120 |
Why?
| | Mutation | 4 | 2014 | 3948 | 0.120 |
Why?
| | Drug Synergism | 2 | 2008 | 379 | 0.120 |
Why?
| | Multiple Pulmonary Nodules | 1 | 2015 | 22 | 0.120 |
Why?
| | Bleomycin | 2 | 2007 | 247 | 0.110 |
Why?
| | Electric Impedance | 1 | 2014 | 109 | 0.110 |
Why?
| | ral GTP-Binding Proteins | 1 | 2013 | 5 | 0.110 |
Why?
| | Bronchiolitis | 1 | 2015 | 91 | 0.110 |
Why?
| | Tyrphostins | 2 | 2004 | 17 | 0.110 |
Why?
| | Forced Expiratory Volume | 1 | 2015 | 527 | 0.100 |
Why?
| | Medical Oncology | 1 | 2016 | 289 | 0.100 |
Why?
| | Transcriptome | 1 | 2019 | 973 | 0.100 |
Why?
| | ras Proteins | 1 | 2013 | 151 | 0.100 |
Why?
| | Protein Binding | 1 | 2019 | 2222 | 0.100 |
Why?
| | Time Factors | 3 | 2011 | 6802 | 0.100 |
Why?
| | Blotting, Western | 3 | 2013 | 1227 | 0.100 |
Why?
| | T-Lymphocytes | 1 | 2021 | 1996 | 0.100 |
Why?
| | Radiography, Thoracic | 1 | 2013 | 168 | 0.100 |
Why?
| | RNA, Small Interfering | 1 | 2014 | 620 | 0.100 |
Why?
| | History, 20th Century | 1 | 2013 | 324 | 0.090 |
Why?
| | B-Lymphocytes | 1 | 2017 | 844 | 0.090 |
Why?
| | Tomography, Spiral Computed | 1 | 2011 | 32 | 0.090 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2012 | 151 | 0.090 |
Why?
| | Cell Division | 2 | 2004 | 795 | 0.090 |
Why?
| | Cell Shape | 1 | 2011 | 58 | 0.090 |
Why?
| | Biopsy, Needle | 1 | 2011 | 191 | 0.090 |
Why?
| | Blood-Air Barrier | 1 | 2011 | 11 | 0.090 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2017 | 1092 | 0.090 |
Why?
| | Fibronectins | 1 | 2011 | 133 | 0.090 |
Why?
| | Collagen Type I | 1 | 2011 | 133 | 0.080 |
Why?
| | Bronchoscopy | 1 | 2011 | 222 | 0.080 |
Why?
| | Survival Rate | 4 | 2013 | 1972 | 0.080 |
Why?
| | Cellular Senescence | 1 | 2012 | 188 | 0.080 |
Why?
| | Proto-Oncogene Proteins | 1 | 2013 | 646 | 0.080 |
Why?
| | Protein Inhibitors of Activated STAT | 1 | 2009 | 6 | 0.080 |
Why?
| | Vena Cava, Superior | 1 | 2009 | 23 | 0.080 |
Why?
| | Cadherins | 1 | 2011 | 205 | 0.080 |
Why?
| | Coronary Vessel Anomalies | 1 | 2009 | 34 | 0.080 |
Why?
| | Pulmonary Alveoli | 1 | 2012 | 405 | 0.080 |
Why?
| | Interleukin-1beta | 1 | 2011 | 371 | 0.080 |
Why?
| | Transcriptional Activation | 1 | 2011 | 379 | 0.080 |
Why?
| | Disease Models, Animal | 2 | 2011 | 4281 | 0.080 |
Why?
| | Asthma | 1 | 2022 | 2285 | 0.070 |
Why?
| | Delivery of Health Care | 1 | 2016 | 948 | 0.070 |
Why?
| | Global Health | 1 | 2011 | 384 | 0.070 |
Why?
| | Electronic Health Records | 1 | 2016 | 1018 | 0.070 |
Why?
| | Colorimetry | 1 | 2008 | 12 | 0.070 |
Why?
| | Oncogene Protein v-akt | 1 | 2008 | 24 | 0.070 |
Why?
| | Antigens, CD | 1 | 2011 | 524 | 0.070 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2008 | 69 | 0.070 |
Why?
| | Indicators and Reagents | 1 | 2008 | 109 | 0.070 |
Why?
| | Occupational Exposure | 1 | 2011 | 342 | 0.070 |
Why?
| | Molecular Chaperones | 1 | 2009 | 196 | 0.070 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2008 | 94 | 0.070 |
Why?
| | Abnormalities, Multiple | 1 | 2009 | 187 | 0.070 |
Why?
| | Mesothelioma | 1 | 2008 | 43 | 0.070 |
Why?
| | Respiration, Artificial | 1 | 2012 | 643 | 0.070 |
Why?
| | Azacitidine | 1 | 2008 | 141 | 0.070 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 2 | 2012 | 1041 | 0.070 |
Why?
| | Comorbidity | 1 | 2011 | 1611 | 0.060 |
Why?
| | Contrast Media | 1 | 2009 | 462 | 0.060 |
Why?
| | Nitrates | 1 | 2006 | 92 | 0.060 |
Why?
| | DNA, Complementary | 1 | 2006 | 269 | 0.060 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2012 | 1460 | 0.060 |
Why?
| | Prognosis | 5 | 2017 | 4011 | 0.060 |
Why?
| | Gene Expression Regulation, Neoplastic | 3 | 2009 | 1400 | 0.060 |
Why?
| | Oxidative Stress | 1 | 2012 | 1302 | 0.060 |
Why?
| | Mice, Inbred C57BL | 2 | 2007 | 5766 | 0.060 |
Why?
| | Lymphatic Metastasis | 2 | 2003 | 349 | 0.060 |
Why?
| | Collagen | 1 | 2007 | 446 | 0.060 |
Why?
| | Biomarkers | 2 | 2017 | 4148 | 0.060 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2014 | 1689 | 0.060 |
Why?
| | Adult | 7 | 2024 | 37595 | 0.060 |
Why?
| | Case-Control Studies | 1 | 2012 | 3528 | 0.060 |
Why?
| | Survival Analysis | 2 | 2005 | 1320 | 0.060 |
Why?
| | Organ Culture Techniques | 1 | 2004 | 156 | 0.060 |
Why?
| | Flavonoids | 1 | 2004 | 83 | 0.050 |
Why?
| | Pruritus | 1 | 2024 | 61 | 0.050 |
Why?
| | Inhibitory Concentration 50 | 1 | 2004 | 90 | 0.050 |
Why?
| | Flow Cytometry | 1 | 2008 | 1185 | 0.050 |
Why?
| | Eczema | 1 | 2024 | 69 | 0.050 |
Why?
| | Exanthema | 1 | 2024 | 77 | 0.050 |
Why?
| | Protein Processing, Post-Translational | 1 | 2006 | 471 | 0.050 |
Why?
| | Biopsy, Fine-Needle | 1 | 2003 | 68 | 0.050 |
Why?
| | Drug Combinations | 1 | 2004 | 339 | 0.050 |
Why?
| | Psoriasis | 1 | 2024 | 102 | 0.050 |
Why?
| | Apoptosis | 2 | 2013 | 2542 | 0.050 |
Why?
| | Predictive Value of Tests | 3 | 2005 | 2030 | 0.050 |
Why?
| | Kinetics | 1 | 2006 | 1679 | 0.050 |
Why?
| | Janus Kinase 3 | 1 | 2002 | 18 | 0.050 |
Why?
| | DNA Methylation | 1 | 2008 | 644 | 0.050 |
Why?
| | Janus Kinase 1 | 1 | 2002 | 24 | 0.050 |
Why?
| | Base Sequence | 1 | 2006 | 2180 | 0.050 |
Why?
| | STAT6 Transcription Factor | 1 | 2002 | 27 | 0.050 |
Why?
| | Iowa | 1 | 2002 | 31 | 0.050 |
Why?
| | Histoplasmosis | 1 | 2002 | 17 | 0.050 |
Why?
| | STAT5 Transcription Factor | 1 | 2002 | 57 | 0.050 |
Why?
| | Lymph Nodes | 2 | 2002 | 493 | 0.050 |
Why?
| | Endosonography | 1 | 2003 | 152 | 0.050 |
Why?
| | Carcinoembryonic Antigen | 1 | 2002 | 39 | 0.050 |
Why?
| | Prospective Studies | 3 | 2022 | 7543 | 0.050 |
Why?
| | Antineoplastic Agents | 2 | 2005 | 2140 | 0.050 |
Why?
| | Cell Polarity | 1 | 2003 | 141 | 0.050 |
Why?
| | Genes, p53 | 1 | 2002 | 72 | 0.050 |
Why?
| | Heart Defects, Congenital | 1 | 2009 | 830 | 0.050 |
Why?
| | Tyrosine | 1 | 2002 | 224 | 0.050 |
Why?
| | Biopsy | 3 | 2016 | 1130 | 0.040 |
Why?
| | Inflammation | 1 | 2012 | 2817 | 0.040 |
Why?
| | Neoplasm Metastasis | 1 | 2003 | 658 | 0.040 |
Why?
| | Protein Transport | 1 | 2002 | 443 | 0.040 |
Why?
| | United States | 2 | 2022 | 14595 | 0.040 |
Why?
| | Fatigue | 1 | 2022 | 329 | 0.040 |
Why?
| | Steroids | 1 | 2021 | 166 | 0.040 |
Why?
| | Biomarkers, Tumor | 1 | 2006 | 1271 | 0.040 |
Why?
| | Mice, Transgenic | 1 | 2005 | 2182 | 0.040 |
Why?
| | Drug Resistance, Neoplasm | 3 | 2014 | 799 | 0.040 |
Why?
| | Skin | 1 | 2024 | 750 | 0.040 |
Why?
| | Cell Nucleus | 1 | 2002 | 615 | 0.040 |
Why?
| | Immunologic Factors | 1 | 2021 | 239 | 0.040 |
Why?
| | Diagnosis, Differential | 1 | 2002 | 1484 | 0.040 |
Why?
| | DNA | 1 | 2004 | 1460 | 0.030 |
Why?
| | Lymphocyte Count | 1 | 2017 | 150 | 0.030 |
Why?
| | Sensitivity and Specificity | 1 | 2002 | 1945 | 0.030 |
Why?
| | Antigen-Presenting Cells | 1 | 2017 | 156 | 0.030 |
Why?
| | Retrospective Studies | 1 | 2015 | 15514 | 0.030 |
Why?
| | Immunophenotyping | 1 | 2017 | 318 | 0.030 |
Why?
| | Disease Progression | 2 | 2016 | 2744 | 0.030 |
Why?
| | Prevalence | 1 | 2002 | 2709 | 0.030 |
Why?
| | Aniline Compounds | 1 | 2014 | 102 | 0.030 |
Why?
| | Immunoenzyme Techniques | 1 | 2013 | 219 | 0.030 |
Why?
| | Lymphocyte Activation | 1 | 2017 | 1150 | 0.030 |
Why?
| | Nitriles | 1 | 2014 | 175 | 0.030 |
Why?
| | Tumor Microenvironment | 1 | 2017 | 682 | 0.030 |
Why?
| | Quinolines | 1 | 2014 | 176 | 0.030 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2013 | 344 | 0.020 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2013 | 270 | 0.020 |
Why?
| | Protein Kinases | 1 | 2014 | 319 | 0.020 |
Why?
| | Mice, Nude | 1 | 2013 | 696 | 0.020 |
Why?
| | Pregnancy | 1 | 2004 | 6715 | 0.020 |
Why?
| | Sequence Analysis, RNA | 1 | 2014 | 451 | 0.020 |
Why?
| | Chronic Disease | 1 | 2016 | 1773 | 0.020 |
Why?
| | Communication | 1 | 2016 | 872 | 0.020 |
Why?
| | Computational Biology | 1 | 2014 | 644 | 0.020 |
Why?
| | Electrophoretic Mobility Shift Assay | 1 | 2009 | 85 | 0.020 |
Why?
| | Immunoprecipitation | 1 | 2009 | 155 | 0.020 |
Why?
| | Fatal Outcome | 1 | 2009 | 305 | 0.020 |
Why?
| | Angiography | 1 | 2009 | 208 | 0.020 |
Why?
| | Plasmids | 1 | 2009 | 363 | 0.020 |
Why?
| | Immunohistochemistry | 2 | 2003 | 1739 | 0.020 |
Why?
| | Registries | 1 | 2016 | 2006 | 0.020 |
Why?
| | Cyclin-Dependent Kinase 4 | 1 | 2007 | 47 | 0.020 |
Why?
| | Up-Regulation | 1 | 2009 | 846 | 0.020 |
Why?
| | Structure-Activity Relationship | 1 | 2007 | 586 | 0.020 |
Why?
| | Echocardiography | 1 | 2009 | 659 | 0.020 |
Why?
| | Mediastinoscopy | 1 | 2005 | 5 | 0.010 |
Why?
| | Polymerase Chain Reaction | 1 | 2008 | 1061 | 0.010 |
Why?
| | Trastuzumab | 1 | 2005 | 101 | 0.010 |
Why?
| | Kaplan-Meier Estimate | 1 | 2006 | 892 | 0.010 |
Why?
| | Electric Conductivity | 1 | 2003 | 95 | 0.010 |
Why?
| | Transcription, Genetic | 1 | 2009 | 1458 | 0.010 |
Why?
| | Multivariate Analysis | 1 | 2006 | 1524 | 0.010 |
Why?
| | Infant | 1 | 2016 | 9408 | 0.010 |
Why?
| | Hypoxia | 1 | 2009 | 1106 | 0.010 |
Why?
| | Trachea | 1 | 2003 | 235 | 0.010 |
Why?
| | Immunoassay | 1 | 2002 | 114 | 0.010 |
Why?
| | Ligands | 1 | 2003 | 665 | 0.010 |
Why?
| | Risk Assessment | 1 | 2009 | 3432 | 0.010 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2005 | 803 | 0.010 |
Why?
| | Rats, Sprague-Dawley | 1 | 2003 | 2500 | 0.010 |
Why?
| | Calcium | 1 | 2003 | 1233 | 0.010 |
Why?
| | Wounds and Injuries | 1 | 2003 | 743 | 0.010 |
Why?
| | Rats | 1 | 2003 | 5675 | 0.010 |
Why?
|
|
Kern's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|